| Nuvoair Medical Pc | |
|
7250 Clearvista Dr Ste 355 Indianapolis IN 46256-5609 | |
| (303) 748-5781 | |
| (888) 915-0624 |
| Full Name | Nuvoair Medical Pc |
|---|---|
| Speciality | Clinic/Center |
| Location | 7250 Clearvista Dr Ste 355, Indianapolis, Indiana |
| Authorized Official Name and Position | Eric J Harker (CEO) |
| Authorized Official Contact | 3037485781 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Nuvoair Medical Pc 50 Milk St Boston MA 02109-5003 Ph: (303) 748-5781 | Nuvoair Medical Pc 7250 Clearvista Dr Ste 355 Indianapolis IN 46256-5609 Ph: (303) 748-5781 |
| NPI Number | 1114627759 |
|---|---|
| Provider Enumeration Date | 03/02/2023 |
| Last Update Date | 03/02/2023 |
| Medicare PECOS PAC ID | 1557742368 |
|---|---|
| Medicare Enrollment ID | O20230425002915 |
News Archive
Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.
From 28% to 68% of women using hormones at menopause take compounded, so-called "bioidentical" hormones, but women don't understand the risks of these unapproved, untested treatments, shows an analysis of two large surveys, which was published online today in Menopause, the journal of The North American Menopause Society.
Cordis Corporation has entered into a distribution agreement with Ostial Solutions for the worldwide distribution of the OSTIAL PRO Stent Positioning System™. The OSTIAL PRO™ is the world's first and only aorto-ostial stent positioning system for coronary and peripheral applications. The OSTIAL PRO™ is intended to optimize the treatment of patients who require a stent implantation for treatment for aorto-ostial blockages.
Glaucoma is one of the leading causes of blindness worldwide. A major risk factor for glaucoma is elevated eye pressure due to poor drainage of aqueous humor, the fluid that provides nutrients to the eye.
As America's obesity epidemic continues to grow, a new study from the University of Colorado Anschutz Medical Campus shows that a low-cost, non-profit weight loss program offers the kind of long-term results that often elude dieters.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114627759 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | (* (Not Available)) | Secondary |
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
| Provider Name | Min Clapham |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1881957207 PECOS PAC ID: 8820237324 Enrollment ID: I20200812002815 |
News Archive
Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.
From 28% to 68% of women using hormones at menopause take compounded, so-called "bioidentical" hormones, but women don't understand the risks of these unapproved, untested treatments, shows an analysis of two large surveys, which was published online today in Menopause, the journal of The North American Menopause Society.
Cordis Corporation has entered into a distribution agreement with Ostial Solutions for the worldwide distribution of the OSTIAL PRO Stent Positioning System™. The OSTIAL PRO™ is the world's first and only aorto-ostial stent positioning system for coronary and peripheral applications. The OSTIAL PRO™ is intended to optimize the treatment of patients who require a stent implantation for treatment for aorto-ostial blockages.
Glaucoma is one of the leading causes of blindness worldwide. A major risk factor for glaucoma is elevated eye pressure due to poor drainage of aqueous humor, the fluid that provides nutrients to the eye.
As America's obesity epidemic continues to grow, a new study from the University of Colorado Anschutz Medical Campus shows that a low-cost, non-profit weight loss program offers the kind of long-term results that often elude dieters.
› Verified 6 days ago
| Provider Name | Eric Harker |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1366572109 PECOS PAC ID: 5698732626 Enrollment ID: I20230609000862 |
News Archive
Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.
From 28% to 68% of women using hormones at menopause take compounded, so-called "bioidentical" hormones, but women don't understand the risks of these unapproved, untested treatments, shows an analysis of two large surveys, which was published online today in Menopause, the journal of The North American Menopause Society.
Cordis Corporation has entered into a distribution agreement with Ostial Solutions for the worldwide distribution of the OSTIAL PRO Stent Positioning System™. The OSTIAL PRO™ is the world's first and only aorto-ostial stent positioning system for coronary and peripheral applications. The OSTIAL PRO™ is intended to optimize the treatment of patients who require a stent implantation for treatment for aorto-ostial blockages.
Glaucoma is one of the leading causes of blindness worldwide. A major risk factor for glaucoma is elevated eye pressure due to poor drainage of aqueous humor, the fluid that provides nutrients to the eye.
As America's obesity epidemic continues to grow, a new study from the University of Colorado Anschutz Medical Campus shows that a low-cost, non-profit weight loss program offers the kind of long-term results that often elude dieters.
› Verified 6 days ago
| Provider Name | Sarah Mckinley |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1124245543 PECOS PAC ID: 8123092897 Enrollment ID: I20230808001226 |
News Archive
Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.
From 28% to 68% of women using hormones at menopause take compounded, so-called "bioidentical" hormones, but women don't understand the risks of these unapproved, untested treatments, shows an analysis of two large surveys, which was published online today in Menopause, the journal of The North American Menopause Society.
Cordis Corporation has entered into a distribution agreement with Ostial Solutions for the worldwide distribution of the OSTIAL PRO Stent Positioning System™. The OSTIAL PRO™ is the world's first and only aorto-ostial stent positioning system for coronary and peripheral applications. The OSTIAL PRO™ is intended to optimize the treatment of patients who require a stent implantation for treatment for aorto-ostial blockages.
Glaucoma is one of the leading causes of blindness worldwide. A major risk factor for glaucoma is elevated eye pressure due to poor drainage of aqueous humor, the fluid that provides nutrients to the eye.
As America's obesity epidemic continues to grow, a new study from the University of Colorado Anschutz Medical Campus shows that a low-cost, non-profit weight loss program offers the kind of long-term results that often elude dieters.
› Verified 6 days ago
| Provider Name | Michael Kenner |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1417912460 PECOS PAC ID: 4082632849 Enrollment ID: I20230814002932 |
News Archive
Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.
From 28% to 68% of women using hormones at menopause take compounded, so-called "bioidentical" hormones, but women don't understand the risks of these unapproved, untested treatments, shows an analysis of two large surveys, which was published online today in Menopause, the journal of The North American Menopause Society.
Cordis Corporation has entered into a distribution agreement with Ostial Solutions for the worldwide distribution of the OSTIAL PRO Stent Positioning System™. The OSTIAL PRO™ is the world's first and only aorto-ostial stent positioning system for coronary and peripheral applications. The OSTIAL PRO™ is intended to optimize the treatment of patients who require a stent implantation for treatment for aorto-ostial blockages.
Glaucoma is one of the leading causes of blindness worldwide. A major risk factor for glaucoma is elevated eye pressure due to poor drainage of aqueous humor, the fluid that provides nutrients to the eye.
As America's obesity epidemic continues to grow, a new study from the University of Colorado Anschutz Medical Campus shows that a low-cost, non-profit weight loss program offers the kind of long-term results that often elude dieters.
› Verified 6 days ago
News Archive
Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.
From 28% to 68% of women using hormones at menopause take compounded, so-called "bioidentical" hormones, but women don't understand the risks of these unapproved, untested treatments, shows an analysis of two large surveys, which was published online today in Menopause, the journal of The North American Menopause Society.
Cordis Corporation has entered into a distribution agreement with Ostial Solutions for the worldwide distribution of the OSTIAL PRO Stent Positioning System™. The OSTIAL PRO™ is the world's first and only aorto-ostial stent positioning system for coronary and peripheral applications. The OSTIAL PRO™ is intended to optimize the treatment of patients who require a stent implantation for treatment for aorto-ostial blockages.
Glaucoma is one of the leading causes of blindness worldwide. A major risk factor for glaucoma is elevated eye pressure due to poor drainage of aqueous humor, the fluid that provides nutrients to the eye.
As America's obesity epidemic continues to grow, a new study from the University of Colorado Anschutz Medical Campus shows that a low-cost, non-profit weight loss program offers the kind of long-term results that often elude dieters.
› Verified 6 days ago
Moazzam Habib Md Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 9240 N Meridian St, Suite 240, Indianapolis, IN 46260 Phone: 317-571-0030 Fax: 317-571-0031 | |
Shalom 56th Street-new Access Point Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 5750 W 56th St, Indianapolis, IN 46254 Phone: 317-291-7422 Fax: 317-291-4912 | |
Franciscan Health Indianapolis & Mooresville Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5230a East Stop 11 Road, Suite 250, Indianapolis, IN 46237 Phone: 317-528-8921 Fax: 317-528-6916 | |
Evernorth Care Providers - Delaware Pa Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 8888 Keystone Xing Ste 1300, Indianapolis, IN 46240 Phone: 773-292-4800 Fax: 312-564-4059 | |
Eskenazi Health Center Cottage Corner Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1434 Shelby St, Indianapolis, IN 46203 Phone: 317-655-3200 Fax: 317-655-3210 | |
Hello Wellness Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1040 E 86th St, Suite 48-a, Indianapolis, IN 46240 Phone: 317-569-1800 | |
Indiana Neurodiagnostics, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9465 Counselors Row, Ste. 200 Office 257, Indianapolis, IN 46240 Phone: 317-614-0310 Fax: 866-279-4704 |